Browse by author
Lookup NU author(s): Dr Robert James
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Since its discovery almost 30 years ago, the mode of action and therapeutic applications of somatostatin have been defined. In particular the cloning and characterization of somatostatin receptor subtypes has facilitated the development of high affinity analogues. In the context of pituitary disease, long-acting somatostatin analogues (octreotide, lanreotide) have been used to treat a variety of pituitary tumours but are most efficacious for the treatment of GH and TSH-secreting adenomas. In patients with acromegaly, depot preparations of these analogues are administered intramuscularly every 10-28 days and provide consistent suppression of GH levels to <5 mU/l in approximately 50-65% of all cases. Even more specific somatostatin receptor analogues are under development. Finally, radiolabelled somatostatin analogue scintigraphy and, in larger doses, therapy, are now established tools in the evaluation and treatment of neuroendocrine tumours.
Author(s): James RA; Stewart PM
Publication type: Article
Publication status: Published
Journal: Best Practice & Research: Clinical Endocrinology & Metabolism
Print publication date: 01/10/1999
ISSN (electronic): 1878-1594
Publisher: Bailliere Tindall
Altmetrics provided by Altmetric